BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Ann Intern Med 2019;170:594-603. [PMID: 30959528 DOI: 10.7326/M18-1715] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Seu R, Riback LR, Nyakowa M, Lizcano J, Musyoki H, Ross J, Cherutich P, Kurth AE, Akiyama MJ. Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya. Glob Public Health 2022;:1-11. [PMID: 35941717 DOI: 10.1080/17441692.2022.2110919] [Reference Citation Analysis]
2 Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS Behav 2022. [PMID: 35776253 DOI: 10.1007/s10461-022-03749-8] [Reference Citation Analysis]
3 Burton HJ, Khatiwada A, Chung D, Meissner EG. Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. South Med J 2022;115:352-7. [PMID: 35649518 DOI: 10.14423/SMJ.0000000000001402] [Reference Citation Analysis]
4 Pericot-valverde I, Heo M, Niu J, Rennert L, Norton BL, Akiyama MJ, Arnsten J, Litwin AH. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder. Drug and Alcohol Dependence 2022;234:109403. [DOI: 10.1016/j.drugalcdep.2022.109403] [Reference Citation Analysis]
5 Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy 2022;102:103588. [DOI: 10.1016/j.drugpo.2022.103588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia S, Smith M, Edlin BR, Marks KM. Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial. JAMA Intern Med 2022. [PMID: 35285851 DOI: 10.1001/jamainternmed.2022.0170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Marshall AD, Rance J, Grebely J, Treloar C. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy 2022;102:103610. [PMID: 35151085 DOI: 10.1016/j.drugpo.2022.103610] [Reference Citation Analysis]
8 Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong'o AW, Kizito KW, Mucara EWK, González Diaz CI, Musyoki H, Mundia B, Cherutich P, Nyakowa M, Lizcano J, Chhun N, Kurth A, Akiyama MJ, Waruiru W, Bhattacharjee P, Cleland C, Donchuk D, Luhmann N, Loarec A, Maman D, Walker J, Vickerman P. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction 2022;117:411-24. [PMID: 34184794 DOI: 10.1111/add.15630] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Adje YH, Brooks KM, Castillo-Mancilla JR, Wyles DL, Anderson PL, Kiser JJ. The use of technology-based adherence monitoring in the treatment of hepatitis C virus. Ther Adv Infect Dis 2022;9:20499361221095664. [PMID: 35591885 DOI: 10.1177/20499361221095664] [Reference Citation Analysis]
10 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
11 Akiyama MJ, Riback L, Reeves JD, Lie YS, Agyemang L, Norton BL, Arnsten JH, Litwin AH. Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. Open Forum Infect Dis 2021;8:ofab474. [PMID: 34692891 DOI: 10.1093/ofid/ofab474] [Reference Citation Analysis]
12 Seaman A, Ronan W, Myers L, Wheelock H, Butler M, Nelson L, E. Williams B, Zaman A. Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.114781] [Reference Citation Analysis]
13 Powell J, Ricco M, Naugle J, Magee C, Hassan H, Masson C, Braimoh G, Zevin B, Khalili M. Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness. Open Forum Infect Dis 2021;8:ofab488. [PMID: 34651053 DOI: 10.1093/ofid/ofab488] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 J Minhas H, Akiyama MJ, Norton BL, Heo M, Arnsten JH, Litwin AH. HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy. AIDS Care 2021;:1-5. [PMID: 34533062 DOI: 10.1080/09540121.2021.1973659] [Reference Citation Analysis]
15 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
17 Sandmann L, Deppe J, Beier C, Ohlendorf V, Schneider J, Wedemeyer H, Wedegärtner F, Cornberg M, Maasoumy B. Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. Open Forum Infect Dis 2021;8:ofab325. [PMID: 34377724 DOI: 10.1093/ofid/ofab325] [Reference Citation Analysis]
18 Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M, Hofer H, Semmo N, Negro F, Zhang Z, Marcinak J, Veitsman E, Hazzan R, Mimidis K, Goulis I, Marques N, Flisiak R, Mazur W, Roncero C, Marra F, Pageaux GP, Asselah T, Lampertico P. Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infect Dis Ther 2021. [PMID: 34125405 DOI: 10.1007/s40121-021-00455-1] [Reference Citation Analysis]
19 Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA; INTRO-HCV Study Group. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Med 2021;18:e1003653. [PMID: 34061883 DOI: 10.1371/journal.pmed.1003653] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
20 Springer SA, Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clin Infect Dis 2020;71:1723-5. [PMID: 32011653 DOI: 10.1093/cid/ciaa111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottilil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis 2020;71:1715-22. [PMID: 32009165 DOI: 10.1093/cid/ciaa105] [Cited by in Crossref: 20] [Cited by in F6Publishing: 40] [Article Influence: 20.0] [Reference Citation Analysis]
22 Nahvi S, Adams TR, Ning Y, Zhang C, Arnsten JH. Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial. Addiction 2021;116:902-13. [PMID: 32857445 DOI: 10.1111/add.15240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Springer SA, Barocas JA, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda. J Infect Dis 2020;222:S230-8. [PMID: 32877568 DOI: 10.1093/infdis/jiz673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
24 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Vega TA, Levander XA, Seaman A, Korthuis PT, Englander H. "Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. J Subst Abuse Treat 2021;127:108337. [PMID: 34134860 DOI: 10.1016/j.jsat.2021.108337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Akiyama MJ, Lipsey D, Ganova-Raeva L, Punkova LT, Agyemang L, Sue A, Ramachandran S, Khudyakov Y, Litwin AH. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy. J Infect Dis 2020;222:488-98. [PMID: 32150621 DOI: 10.1093/infdis/jiaa100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Drug Alcohol Depend 2021;220:108525. [PMID: 33461152 DOI: 10.1016/j.drugalcdep.2021.108525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Assoumou SA, Sian CR, Gebel CM, Linas BP, Samet JH, Bernstein JA. Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study. Drug Alcohol Depend 2021;220:108526. [PMID: 33465604 DOI: 10.1016/j.drugalcdep.2021.108526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Springer SA. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder. Clin Infect Dis 2020;70:2703-5. [PMID: 31346595 DOI: 10.1093/cid/ciz695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Akiyama MJ, Lipsey D, Heo M, Agyemang L, Norton BL, Hidalgo J, Lora K, Litwin AH. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy. Clin Infect Dis 2020;70:2695-702. [PMID: 31346609 DOI: 10.1093/cid/ciz693] [Cited by in Crossref: 19] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
31 Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis 2020;70:1397-405. [PMID: 31095683 DOI: 10.1093/cid/ciz384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Norton BL, Litwin AH. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States. Clin Infect Dis 2020;70:2366-8. [PMID: 31513706 DOI: 10.1093/cid/ciz701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Pericot-Valverde I, Heo M, Niu J, Norton BL, Akiyama MJ, Agyemang L, Litwin AH. Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy. Open Forum Infect Dis 2020;7:ofaa380. [PMID: 33381611 DOI: 10.1093/ofid/ofaa380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Abdelwadoud M, Mattingly TJ 2nd, Seguí HA, Gorman EF, Perfetto EM. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. Patient 2021;14:471-84. [PMID: 33372245 DOI: 10.1007/s40271-020-00489-6] [Reference Citation Analysis]
35 Patel AA, Bui A, Prohl E, Bhattacharya D, Wang S, Branch AD, Perumalswami PV. Innovations in Hepatitis C Screening and Treatment. Hepatol Commun 2021;5:371-86. [PMID: 33681673 DOI: 10.1002/hep4.1646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pericot-Valverde I, Heo M, Akiyama MJ, Norton BL, Agyemang L, Niu J, Litwin AH. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial. BMC Infect Dis 2020;20:928. [PMID: 33276738 DOI: 10.1186/s12879-020-05667-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis 2021;8:ofaa564. [PMID: 33447634 DOI: 10.1093/ofid/ofaa564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
38 Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 2020;4:964-9. [PMID: 33102771 DOI: 10.1002/jgh3.12376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Peckham AM, Young EH. Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review. Open Forum Infect Dis 2020;7:ofaa503. [PMID: 33241069 DOI: 10.1093/ofid/ofaa503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Adv Ther 2020;37:4033-42. [PMID: 32754824 DOI: 10.1007/s12325-020-01449-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
41 Norton BL, Akiyama MJ, Agyemang L, Heo M, Pericot-Valverde I, Litwin AH. Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents. Open Forum Infect Dis 2020;7:ofaa377. [PMID: 33134406 DOI: 10.1093/ofid/ofaa377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
42 Litwin AH, Shafner L, Norton B, Akiyama MJ, Agyemang L, Guzman M, Vera T, Heo M. Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study. Open Forum Infect Dis 2020;7:ofaa290. [PMID: 32818140 DOI: 10.1093/ofid/ofaa290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Chan J, Schwartz J, Kaba F, Bocour A, Akiyama MJ, Hobstetter L, Rosner Z, Winters A, Yang P, MacDonald R. Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care. Open Forum Infect Dis 2020;7:ofaa263. [PMID: 33123613 DOI: 10.1093/ofid/ofaa263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
44 Verma M, Chu JN, Salama JAF, Faiz MT, Eweje F, Gwynne D, Lopes A, Hess K, Soares V, Steiger C, McManus R, Koeppen R, Hua T, Hayward A, Collins J, Tamang SM, Ishida K, Miller JB, Katz S, Slocum AH, Sulkowski MS, Thomas DL, Langer R, Traverso G. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Proc Natl Acad Sci U S A 2020;117:11987-94. [PMID: 32424082 DOI: 10.1073/pnas.2004746117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
45 Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? Am J Addict 2020;29:249-67. [PMID: 32346932 DOI: 10.1111/ajad.13051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Serper M, Evon DM, Stewart PW, Lok AS, Amador J, Reeve BB, Golin CE, Fried MW, Reddy KR, Sterling RK, Sarkar S, Di Bisceglie AM, Lim JK, Nelson DR, Reau N. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med 2020;35:1011-20. [PMID: 31659661 DOI: 10.1007/s11606-019-05394-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]